Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AM Rx vs OlleveCare

AM Rx
Graded #491

Higher grade

vs+3.3999999999999986
OlleveCare
Graded #497

Lower grade

The verdict

AM Rx takes it — 49.6/100 to 46.2/100.

AM Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. AM Rx (getamrx.com) is a telehealth platform operated by FitRX, LLC (also operates Zealthy and FitRx).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAM Rx +5
50
45
Dose & formulationAM Rx +25
65
40
Clinical oversightOlleveCare +12
41
53
Labs & monitoringEven
49
49
FulfillmentAM Rx +20
58
38
Contract termsOlleveCare +35
20
55
AM Rx · left barOlleveCare · right bar

The numbers

MetricAM RxOlleveCare
WeighScore49.6/10046.2/100
GradeCC
Scorecard rank#491#497
Semaglutide$151/mo (quarterly plan, plus a separate fee, compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not published13 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
AM Rx

Graded #491 · C

Strengths

  • Insurance coordination for brand-name GLP-1s — as low as $25/mo
  • All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
  • HSA and FSA accepted
  • Video visits available with providers averaging 10+ years' experience
  • Compounded semaglutide from $151/mo on the quarterly plan

Where it loses points

  • Active FTC/DOJ lawsuit over deceptive billing and subscription practices
  • Novo Nordisk false-advertising lawsuit (Aug 2025)
  • Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
  • Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
OlleveCare

Graded #497 · C

Strengths

  • 13 states listed explicitly (VA, FL, AZ, MA, HI, IA, MD, NM, WA, KS, NY, DC, ID)
  • Both semaglutide and tirzepatide offered — switch molecules without switching platforms
  • Multi-service platform — GLP-1, virtual urgent care, and non-controlled refills with one provider
  • Cash-pay with a superbill option for out-of-network reimbursement
  • Founder Ahmed Emam is named in the footer

Where it loses points

  • Legal entity name not disclosed anywhere — can't be verified in a state registry
  • Pricing not shown before booking — you must enter the intake flow to see the fee
  • Pharmacy partner not named; model appears to fill at your preferred retail pharmacy
  • No medical director or prescribing clinician named — only 'board-certified providers'
  • No LegitScript badge, BBB profile, or HIPAA/SOC 2 seals displayed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard